Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We've made it easier for you to connect! Fill out your NEW profile.

New BCO Content on Recently Approved Immunotherapy Jemperli

Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available.

Jemperli also is approved to treat dMMR advanced-stage endometrial cancer that has grown after treatment with platinum chemotherapy.

Learn more about:

Read more.